10x Genomics, Inc.
US ˙ NasdaqGS ˙ US88025U1097

SecurityTXG / 10x Genomics, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership37,655 shares
Latest Disclosed Value $ 799,416
Qube Research & Technologies Ltd reports 84.67% decrease in ownership of TXG / 10x Genomics, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 37,655 shares of 10x Genomics, Inc. (US:TXG) valued at $799,416 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 245,636 shares of 10x Genomics, Inc.. This represents a change in shares of -84.67% during the quarter. The current value of the position is $1,210,985 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F 10X GENOMICS CL A COM 88025U109 37,655 -207,981 -84.67 799 -80.05 0.0009
2026-02-17 2025-12-31 13F 10X GENOMICS CL A COM 88025U109 245,636 135,492 123.01 4,006 211.27 0.0041
2025-11-14 2025-09-30 13F 10X GENOMICS CL A COM 88025U109 110,144 110,144 1,288 0.0013
2025-02-14 2024-12-31 13F 10X GENOMICS CL A COM 88025U109 0 -65,225 -100.00 0 -100.00
2024-11-14 2024-09-30 13F 10X GENOMICS CL A COM 88025U109 65,225 -554,777 -89.48 1,473 -87.79 0.0022
2024-08-14 2024-06-30 13F 10X GENOMICS CL A COM 88025U109 620,002 236,298 61.58 12,059 -16.26 0.0191
2024-05-14 2024-03-31 13F 10X GENOMICS CL A COM 88025U109 383,704 383,704 14,400 0.0228
2023-11-13 2023-09-30 13F 10X GENOMICS CL A COM 88025U109 0 -17,022 -100.00 0 -100.00
2023-08-14 2023-06-30 13F 10X GENOMICS CL A COM 88025U109 17,022 17,022 951 0.0035
2023-05-15 2023-03-31 13F 10X GENOMICS CL A COM 88025U109 0 -33,697 -100.00 0 -100.00
2023-02-14 2022-12-31 13F 10X GENOMICS CL A COM 88025U109 33,697 33,697 1,228 0.0066
2021-11-12 2021-09-30 13F 10X GENOMICS CL A COM 88025U109 0 -13,573 -100.00 0 -100.00
2021-08-13 2021-06-30 13F 10X GENOMICS CL A COM 88025U109 13,573 13,573 2,658 0.0303
2021-05-14 2021-03-31 13F 10X GENOMICS CL A COM 88025U109 0 -16,685 -100.00 0 -100.00
2021-02-16 2020-12-31 13F 10X GENOMICS CL A COM 88025U109 16,685 12,227 274.27 2,363 325.00 0.0336
2020-11-12 2020-09-30 13F 10X GENOMICS CL A COM 88025U109 4,458 4,458 556 0.0079
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.